Back To Search Results

Becker Muscular Dystrophy

Editor: Krishna Kishore Umapathi Updated: 7/19/2023 4:57:18 PM

Becker muscular dystrophy (BMD) is an X-linked recessive disorder due to mutation in the dystrophin gene that results in progressive muscle degeneration and proximal muscle weakness.[1][2] This condition is less common and less severe than Duchenne muscular dystrophy (DMD). The onset of symptoms is late compared to Duchenne muscular dystrophy, although it varies widely between 5 to 60 years of age. In an investigation done in 67 patients exercising a standard protocol, the milder group had been found ambulant untll their forties or beyond and more severe group with the earlier loss of ambulation.[3]


Earn CME credit as you help guide your clinical decisions.
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed.


$59 per month


$599 per year

Becker muscular dystrophy is caused by a mutation in a protein called dystrophin. The defective gene is located in the Xp21.2 chromosome, and the defect is inherited as an X-linked recessive trait. Patients without a clear X-linked pattern of inheritance may have defects in other genes, affecting the dystrophin-associated glycoproteins.

Becker muscular dystrophy is a rare disease almost exclusively in males due to X-linked inheritance. The worldwide prevalence of Duchenne and Becker muscular dystrophy ranges from 0.1 to 1.8 per 10000 male individuals. According to research conducted in the United States in 2010, the prevalence of BMD for all age groups was 0.26 per 10000 male individuals, and it was found more common among non-Hispanic whites than non-Hispanic blacks. The study of Becker muscular dystrophy (per 10000 males) suggests the prevalence of 0.01 in South Africa, 0.1 to 0.2 in Asia, and 0.1 to 0.7 in European countries. Isolated data shows Becker muscular dystrophy is three times less common than Duchenne muscular dystrophy.[4]

Dystrophin is a rod-shaped protein present in the cytoplasmic side of muscle fibers cell membrane as a part of a glycoprotein complex that connects the cytoskeleton to the extracellular matrix. It provides mechanical reinforcement and stabilizes the cell membrane.[2] Becker muscular dystrophy is caused by mutation in the dystrophin gene more commonly deletions (65% to 70%) or duplications (5% to 10%), which results in nonfunctional or less production of dystrophin.[5] The dystrophin gene consists of 79 exons in Xp21 spans more than 2200 kb.[6][7] There are more chances of mutation during meiosis due to a large number of base pairs (around 2 million base pairs). Other forms of mutations, like small deletions and insertions, small site variants, are also present in small numbers.[8] Disruption of the dystrophin-glycoprotein complex leads to loss of cell membrane and degeneration of myofibers.

Neuronal nitric oxide (nNOS) is secured as a part of the dystrophin-glycoprotein complex that produces nitric oxide, which regulates vasodilation and increases blood flow to the muscle. The absence of dystrophin causes loss of neuronal nitric oxide associated with exercise-induced muscle weakness and fatigue.[9][10]

Damage to the cell membrane causes the outflow of creatine kinase from inside the cell, and the influx of calcium ions into the cell due to markedly increased open probability of leak channels.[11] Inflammatory mediators aid in the overexpression of inducible nitric oxide synthase (iNOS) and increased production of nitric oxide. Nitrosylation destabilizes the ryanodine receptor (RyR1) of the sarcoplasmic reticulum, followed by calcium leakage in the cytosol. Increased cellular calcium ion concentration activates calpains that mediate protein degradation.[12][13]

On microscopic examination, the hallmark of Becker muscular dystrophy is ongoing myofiber necrosis and regeneration. Active muscle fiber necrosis and cluster of basophilic regenerating fibers are more prominent in younger age. In contrast, myofiber splitting with necrosis, increased internal nuclei, fiber hypertrophy, fatty replacement, and endomysia fibrosis are conspicuous in older age.[14][15]

History and Physical

There is a significant variation in clinical presentation and the onset of symptoms. Some patients retain ambulation untll old age and some present earlier. Growth is slower, leading to short stature. Obtaining a complete family history assists in genetic counseling. Becker muscular dystrophy has a milder clinical course and later onset than Duchenne muscular dystrophy. Suspicion of BMD is made when a child presents with muscle weakness selectively affecting proximal earlier than distal limb muscles and lower limbs before upper limbs with positive family history. Patients may present with symptoms like cramping with strenuous activity, the delayed ability of jumping, running, stair climbing, and cognitive impairment.[16] The intelligence quotient (IQ) of around 20% to 25% of patients is less than 70. Elbow fractures, cardiomyopathies, toe walking may be seen later in life as BMD is a progressive disease. Cardiomyopathy is characterized by fibrosis of the wall of the left ventricle, which can further lead to the development of life-threatening arrhythmias.

On physical examination, atrophy with pseudohypertrophy of calf muscles and occasionally quadriceps, hypotonia, hyporeflexia, fasciculations, Gower sign (use their hands and arms support to push them upright from squatting position), lumbar lordosis, shortening of Achilles tendons along with contractures of joints like knee, elbows, and hips are the common findings.[16][17] Pseudohypertrophy is due to the fibrosis and fatty replacement of atrophic muscles, which is a classical feature. Besides calf muscle hypertrophy of forearm muscle and tongue is also found in rare instances.

Female carriers may only present with cardiomyopathy. Sometimes carrier females may have mild muscle weakness. Approximately 22 percent of carriers become symptomatic with a high degree of variability. Genetic analysis is required for proper investigation of a mutation in case of suspicion.


When muscular dystrophy is suspected after history and examination, creatinine kinase level followed by dystrophin gene deletion analysis or muscle biopsy with dystrophin antibody staining is the mainstay of the laboratory studies to confirm the diagnosis.[16] However, in most instances, muscle biopsy is avoided, and genetic testing is confirmatory.

Creatinine Kinase (CK) Level

Raised creatinine kinase level indicates muscle degeneration, attaining a maximum of around 10 to 15 yrs of age.[6] Creatinine level is raised five times or more above the normal.

Genetic Analysis

Genetic analysis is usually sufficient for diagnosis and commonly used in the modern era. This is performed for the detection of deletions and duplications by several methods such as Multiplex ligation-dependant probe amplification (MLPA), fluorescence in situ hybridization (FISH), and polymerase chain reaction (PCR).[18][19] Among them, MLPA is the mainstay of methods that are mostly used for diagnosis. However, muscle biopsy with dystrophin can still be useful in cases of negative genetic analysis. In sporadic cases, the genetic analysis should be performed first for diagnosis. In familial cases in which gene mutation has already been revealed, diagnosis is straightforward.


Electromyography may be indicated to differentiate between primary nerve process disease and myopathy, identifying the muscle group for optimal biopsy. However, electromyography is almost never used in diagnosis.

Muscle Biopsy

Muscle histology reveals necrosis, regeneration, fatty replacement, endomysial fibrosis but is not specific for diagnosis.[20][15]

Electrocardiograms (ECG)

Electrocardiograms are an important part of surveillance for supraventricular and ventricular arrhythmias in cardiomyopathies or symptomatic patients.

Other Tests

Liver function tests for transaminases, pulmonary function tests, and spinal radiographs to follow the progression of scoliosis are also important but less important.

Treatment / Management

Becker muscular dystrophy has no curative treatment, and supportive therapy, along with rehabilitation, is the mainstay of treatment. Many clinical trials for gene therapy are still in progress.


Corticosteroid (prednisolone at a dose of 0.75 mg/kg/day or deflazacort at a dose of 0.9 mg/kg/day) has been the mainstay of treatment.[16][21][22] Corticosteroids should be started before physical disability and continue even after the loss of ambulation and in more severe cases.[16] It is beneficial for improving pulmonary function, delays scoliosis (decreases the need for surgery), delaying the onset of cardiomyopathy, and prolongs survival.[23][24] Corticosteroid dose should be reduced by 25% to 33% in case of side effects.[16] Nitric oxide has become the drug of treatment in some cases to increase the blood supply to muscles through vasodilation.

Medical Treatment

Tracheostomy and assisted ventilation are needed for patients with respiratory failure, and treatment of cardiomyopathy with ACE inhibitors and beta-blockers can help prolong survival.[25]


Interprofessional care is provided to facilitate multiple specialized assessments and interventions to improve the quality of life. Interprofessional care includes physical therapy to strengthen the motor activity along with speech therapy, occupational therapy, and recreational therapy.

Endocrine Management

In case of impaired growth and delayed puberty, advice from endocrinologists plays a crucial role in the development of the child.[16]

Surgical Management

Progressive scoliosis and contracture require surgical intervention to prolong ambulation.[25]

Differential Diagnosis

Becker muscular dystrophy has to be distinguished from other myopathies with muscle weakness as presenting symptoms.

Duchenne Muscular Dystrophy: More severe and early onset than BMD. The patient becomes wheelchair-bound earlier, and the length of survival is shorter. Patients usually have lower dystrophin concentration.[26]

Polymyositis: This is the idiopathic inflammatory myopathy characterized by bilateral proximal muscle weakness that may confuse this condition with BMD, but the absence of distal pseudohypertrophy helps in differentiating it from BMD.[27]

Spinal Muscular Atrophy: This is an autosomal-recessive inherited disorder with hyporeflexia, tongue fasciculations, weakness in bulbar, or brainstem muscles are more common but have less cognitive impairment. The absence of dystrophin gene mutation in a DNA probe provokes spinal muscular atrophy as an alternative diagnosis.[28]

Limb-girdle Muscular Dystrophy: This condition is hard to differentiate from BMD; however, calf muscle pseudohypertrophy is absent.[29]

Dilated Cardiomyopathy: Muscular dystrophy results in cardiomyopathy, which is one of the most serious complications and the leading cause of mortality. But dilated cardiomyopathy can be a separate entity with a different genetic etiology or from other causes apart from muscular dystrophy.[30]

Emery-Dreyfuss Muscular Dystrophy: Early contractures and cardiac defects help to distinguish it from BMD. Humeroperineal muscle weakness and wasting begin in the first and second decades of life.[31]

Myasthenia Gravis: Fluctuating skeletal muscle weakness simulate the clinical presentation of BMD, but facial weakness, ptosis, and diplopia are common. However, infrequent proximal muscle weakness alone may occur.[32]

Metabolic Myopathies: Metabolic myopathies are the storage diseases caused by the deficiency of enzymes required for the metabolism of glycogen, lipids, and mitochondrial diseases. Most patients complain about muscle weakness and pain during physical activity rather than during rest.[33]


Patients with Becker muscular dystrophy have a less severe and milder clinical course than Duchenne muscular dystrophy. Chances of survival decrease with time as the disease progresses. Thus supportive interventions help prolong life. The average life expectancy of the patient with Becker muscular dystrophy is about 40 to 50 years. Death is most commonly due to dilated cardiomyopathy.[34]


Progressive deterioration of the disease process is complicated by cardiomyopathy, progressive loss of pulmonary and liver functions, loss of ambulation, cognitive impairment, and bone fractures. All patients have a high chance of postoperative chest infections.[25] Rhabdomyolysis leads to myoglobinuria and subsequent kidney failure. The use of corticosteroids causes adrenal insufficiency and immunosuppression.

Deterrence and Patient Education

Late medical, rehabilitative, and surgical interventions worsen this condition. So patients and families should be made aware of the disease and encouraged to approach the healthcare facilities as soon as possible. Prolonged use of corticosteroids increases the toxicity, so an initial discussion should be done with the family before the use of steroids. The family should be educated about the signs and symptoms of toxicity.[16] The patient must have access to complete information about treatment options and tests. Consultations should be done if the carrier mother wants to have a child. Genetic counseling and specialist clinical genetic advice are vital. Patients should be educated early about the disease and should be provided with truthful expectations about the disease process and outcomes. Guide them with the need for regular follow-up and physical therapy.

Enhancing Healthcare Team Outcomes

Although Becker muscular dystrophy is a rare condition, the clinical presentation gives high suspicion of the disease. But, a wide range of symptoms necessitates the efforts of an interprofessional healthcare team. Especially the patients having more severe conditions should care under the intervention of physiotherapists, vocational trainers, nurses, clinicians, nutritionists, radiologists, pharmacists, speech therapists, recreational therapists, cardiologists, pulmonologists, neurologists, and genetic experts. Genetic analysis needs precise evaluation to get accurate results for diagnosis. Pharmacists should make sure that the patient is receiving glucocorticoids, working with other health professionals on dosing, administration, and side effects. The interaction between health professionals is essential to improving patient outcomes.



Worton R. Muscular dystrophies: diseases of the dystrophin-glycoprotein complex. Science (New York, N.Y.). 1995 Nov 3:270(5237):755-6     [PubMed PMID: 7481760]


Ervasti JM, Ohlendieck K, Kahl SD, Gaver MG, Campbell KP. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature. 1990 May 24:345(6273):315-9     [PubMed PMID: 2188135]


Bushby KM, Gardner-Medwin D. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. Journal of neurology. 1993 Feb:240(2):98-104     [PubMed PMID: 8437027]


Romitti PA, Zhu Y, Puzhankara S, James KA, Nabukera SK, Zamba GK, Ciafaloni E, Cunniff C, Druschel CM, Mathews KD, Matthews DJ, Meaney FJ, Andrews JG, Conway KM, Fox DJ, Street N, Adams MM, Bolen J, MD STARnet. Prevalence of Duchenne and Becker muscular dystrophies in the United States. Pediatrics. 2015 Mar:135(3):513-21. doi: 10.1542/peds.2014-2044. Epub 2015 Feb 16     [PubMed PMID: 25687144]


Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle & nerve. 2006 Aug:34(2):135-44     [PubMed PMID: 16770791]

Level 3 (low-level) evidence


Flanigan KM. Duchenne and Becker muscular dystrophies. Neurologic clinics. 2014 Aug:32(3):671-88, viii. doi: 10.1016/j.ncl.2014.05.002. Epub     [PubMed PMID: 25037084]


Hegde MR, Chin EL, Mulle JG, Okou DT, Warren ST, Zwick ME. Microarray-based mutation detection in the dystrophin gene. Human mutation. 2008 Sep:29(9):1091-9. doi: 10.1002/humu.20831. Epub     [PubMed PMID: 18663755]


Takeshima Y, Yagi M, Okizuka Y, Awano H, Zhang Z, Yamauchi Y, Nishio H, Matsuo M. Mutation spectrum of the dystrophin gene in 442 Duchenne/Becker muscular dystrophy cases from one Japanese referral center. Journal of human genetics. 2010 Jun:55(6):379-88. doi: 10.1038/jhg.2010.49. Epub 2010 May 20     [PubMed PMID: 20485447]

Level 3 (low-level) evidence


Sander M, Chavoshan B, Harris SA, Iannaccone ST, Stull JT, Thomas GD, Victor RG. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proceedings of the National Academy of Sciences of the United States of America. 2000 Dec 5:97(25):13818-23     [PubMed PMID: 11087833]


Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, Judge L, Bostick B, Chamberlain JS, Terjung RL, Duan D. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. The Journal of clinical investigation. 2009 Mar:119(3):624-35. doi: 10.1172/JCI36612. Epub 2009 Feb 23     [PubMed PMID: 19229108]


Fong PY, Turner PR, Denetclaw WF, Steinhardt RA. Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin. Science (New York, N.Y.). 1990 Nov 2:250(4981):673-6     [PubMed PMID: 2173137]


Bellinger AM, Reiken S, Carlson C, Mongillo M, Liu X, Rothman L, Matecki S, Lacampagne A, Marks AR. Hypernitrosylated ryanodine receptor calcium release channels are leaky in dystrophic muscle. Nature medicine. 2009 Mar:15(3):325-30. doi: 10.1038/nm.1916. Epub 2009 Feb 8     [PubMed PMID: 19198614]


Tidball JG, Villalta SA. NO may prompt calcium leakage in dystrophic muscle. Nature medicine. 2009 Mar:15(3):243-4. doi: 10.1038/nm0309-243. Epub     [PubMed PMID: 19265820]


Kaido M, Arahata K, Hoffman EP, Nonaka I, Sugita H. Muscle histology in Becker muscular dystrophy. Muscle & nerve. 1991 Nov:14(11):1067-73     [PubMed PMID: 1745279]


Bell CD,Conen PE, Histopathological changes in Duchenne muscular dystrophy. Journal of the neurological sciences. 1968 Nov-Dec;     [PubMed PMID: 5709861]


Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, Case LE, Clemens PR, Hadjiyannakis S, Pandya S, Street N, Tomezsko J, Wagner KR, Ward LM, Weber DR, DMD Care Considerations Working Group. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. The Lancet. Neurology. 2018 Mar:17(3):251-267. doi: 10.1016/S1474-4422(18)30024-3. Epub 2018 Feb 3     [PubMed PMID: 29395989]

Level 3 (low-level) evidence


Shrestha S, Munakomi S. Gower Sign. StatPearls. 2023 Jan:():     [PubMed PMID: 31082017]


Gatta V, Scarciolla O, Gaspari AR, Palka C, De Angelis MV, Di Muzio A, Guanciali-Franchi P, Calabrese G, Uncini A, Stuppia L. Identification of deletions and duplications of the DMD gene in affected males and carrier females by multiple ligation probe amplification (MLPA). Human genetics. 2005 Jun:117(1):92-8     [PubMed PMID: 15841391]


Hwa HL, Chang YY, Chen CH, Kao YS, Jong YJ, Chao MC, Ko TM. Multiplex ligation-dependent probe amplification identification of deletions and duplications of the Duchenne muscular dystrophy gene in Taiwanese subjects. Journal of the Formosan Medical Association = Taiwan yi zhi. 2007 May:106(5):339-46     [PubMed PMID: 17561468]


Hoffman EP, Kunkel LM, Angelini C, Clarke A, Johnson M, Harris JB. Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology. 1989 Aug:39(8):1011-7     [PubMed PMID: 2668783]


Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, Jain M, Kleijnen J. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet journal of rare diseases. 2017 Apr 26:12(1):79. doi: 10.1186/s13023-017-0631-3. Epub 2017 Apr 26     [PubMed PMID: 28446219]


Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. Journal of paediatrics and child health. 2015 Aug:51(8):759-64. doi: 10.1111/jpc.12868. Epub 2015 Mar 9     [PubMed PMID: 25752877]


Gloss D, Moxley RT 3rd, Ashwal S, Oskoui M. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016 Feb 2:86(5):465-72. doi: 10.1212/WNL.0000000000002337. Epub     [PubMed PMID: 26833937]

Level 1 (high-level) evidence


Biggar WD, Harris VA, Eliasoph L, Alman B. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscular disorders : NMD. 2006 Apr:16(4):249-55     [PubMed PMID: 16545568]


Emery AE. The muscular dystrophies. Lancet (London, England). 2002 Feb 23:359(9307):687-95     [PubMed PMID: 11879882]


Alvarez Leal M, Hernández Sifuentes PM, Pérez-Zuno JA. [Differential diagnosis of Becker and Duchenne muscular dystrophy]. Gaceta medica de Mexico. 1994 Nov-Dec:130(6):454-8     [PubMed PMID: 7557060]


Furuya T, Tateishi M, Hara M, Kashiwazaki S, Takeuchi M. [Differential diagnosis of Becker-type muscular dystrophy from polymyositis]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine. 1996 Jun 10:85(6):927-9     [PubMed PMID: 8753060]


Lunt PW, Cumming WJ, Kingston H, Read AP, Mountford RC, Mahon M, Harris R. DNA probes in differential diagnosis of Becker muscular dystrophy and spinal muscular atrophy. Lancet (London, England). 1989 Jan 7:1(8628):46-7     [PubMed PMID: 2563028]


Norman A, Thomas N, Coakley J, Harper P. Distinction of Becker from limb-girdle muscular dystrophy by means of dystrophin cDNA probes. Lancet (London, England). 1989 Mar 4:1(8636):466-8     [PubMed PMID: 2563842]


Dec GW, Fuster V. Idiopathic dilated cardiomyopathy. The New England journal of medicine. 1994 Dec 8:331(23):1564-75     [PubMed PMID: 7969328]


Puckelwartz M, McNally EM. Emery-Dreifuss muscular dystrophy. Handbook of clinical neurology. 2011:101():155-66. doi: 10.1016/B978-0-08-045031-5.00012-8. Epub     [PubMed PMID: 21496632]


Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet (London, England). 2001 Jun 30:357(9274):2122-8     [PubMed PMID: 11445126]


Tarnopolsky MA. Metabolic Myopathies. Continuum (Minneapolis, Minn.). 2016 Dec:22(6, Muscle and Neuromuscular Junction Disorders):1829-1851     [PubMed PMID: 27922496]


Cox GF, Kunkel LM. Dystrophies and heart disease. Current opinion in cardiology. 1997 May:12(3):329-43     [PubMed PMID: 9243091]

Level 3 (low-level) evidence